Literature DB >> 23241412

Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Yao Wang1, Manabu Niimi, Kazutoshi Nishijima, Ahmed Bilal Waqar, Ying Yu, Tomonari Koike, Shuji Kitajima, Enqi Liu, Tomohiro Inoue, Masayuki Kohashi, Yuka Keyamura, Tomohiro Yoshikawa, Jifeng Zhang, Loretta Ma, Xiaohui Zha, Teruo Watanabe, Yujiro Asada, Y Eugene Chen, Jianglin Fan.   

Abstract

OBJECTIVE: Apolipoprotein (apo) A-II is the second major apo of high-density lipoproteins, yet its pathophysiological roles in the development of atherosclerosis remain unknown. We aimed to examine whether apo A-II plays any role in atherogenesis and, if so, to elucidate the mechanism involved. METHODS AND
RESULTS: We compared the susceptibility of human apo A-II transgenic (Tg) rabbits to cholesterol diet-induced atherosclerosis with non-Tg littermate rabbits. Tg rabbits developed significantly less aortic and coronary atherosclerosis than their non-Tg littermates, while total plasma cholesterol levels were similar. Atherosclerotic lesions of Tg rabbits were characterized by reduced macrophages and smooth muscle cells, and apo A-II immunoreactive proteins were frequently detected in the lesions. Tg rabbits exhibited low levels of plasma C-reactive protein and blood leukocytes compared with non-Tg rabbits, and high-density lipoproteins of Tg rabbit plasma exerted stronger cholesterol efflux activity and inhibitory effects on the inflammatory cytokine expression by macrophages in vitro than high-density lipoproteins isolated from non-Tg rabbits. In addition, β-very-low-density lipoproteins of Tg rabbits were less sensitive to copper-induced oxidation than β-very-low-density lipoproteins of non-Tg rabbits.
CONCLUSIONS: These results suggest that enrichment of apo A-II in high-density lipoprotein particles has atheroprotective effects and apo A-II may become a target for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241412      PMCID: PMC3673010          DOI: 10.1161/ATVBAHA.112.300445

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI.

Authors:  M C de Beer; D M Durbin; L Cai; N Mirocha; A Jonas; N R Webb; F C de Beer; D R van Der Westhuyzen
Journal:  J Biol Chem       Date:  2001-02-09       Impact factor: 5.157

2.  A splice-junction mutation responsible for familial apolipoprotein A-II deficiency.

Authors:  S S Deeb; K Takata; R L Peng; G Kajiyama; J J Albers
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

3.  Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction.

Authors:  J E Buring; G T O'Connor; S Z Goldhaber; B Rosner; P N Herbert; C B Blum; J L Breslow; C H Hennekens
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

4.  Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells.

Authors:  Natalie Fournier; Anne Cogny; Véronique Atger; Danièle Pastier; Dominique Goudouneche; Antonino Nicoletti; Nicole Moatti; Jean Chambaz; Jean-Louis Paul; Athina-Despina Kalopissis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

5.  Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Authors:  Vicent Ribas; José Luis Sánchez-Quesada; Rosa Antón; Mercedes Camacho; Josep Julve; Joan Carles Escolà-Gil; Luís Vila; Jordi Ordóñez-Llanos; Francisco Blanco-Vaca
Journal:  Circ Res       Date:  2004-09-23       Impact factor: 17.367

6.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

Review 7.  Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis.

Authors:  N E Miller
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

8.  Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol efflux.

Authors:  S Oikawa; A J Mendez; J F Oram; E L Bierman; M C Cheung
Journal:  Biochim Biophys Acta       Date:  1993-01-10

9.  Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis.

Authors:  Tomonaga Ichikawa; Shuji Kitajima; Jingyan Liang; Tomonari Koike; Xiaofei Wang; Huijun Sun; Mitsuyo Okazaki; Masatoshi Morimoto; Hisataka Shikama; Teruo Watanabe; Nobuhiro Yamada; Jianglin Fan
Journal:  Lab Invest       Date:  2004-06       Impact factor: 5.662

10.  Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP-AI/AII.

Authors:  W J Johnson; E P Kilsdonk; A van Tol; M C Phillips; G H Rothblat
Journal:  J Lipid Res       Date:  1991-12       Impact factor: 5.922

View more
  32 in total

1.  Setting the course for apoAII: a port in sight?

Authors:  Henry J Pownall; Baiba K Gillard; Antonio M Gotto
Journal:  Clin Lipidol       Date:  2013-10

2.  The interaction between ApoA2 -265T>C polymorphism and dietary fatty acids intake on oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Elham Zamani; Haleh Sadrzadeh-Yeganeh; Gity Sotoudeh; Laleh Keramat; Mohammadreza Eshraghian; Masoumeh Rafiee; Fariba Koohdani
Journal:  Eur J Nutr       Date:  2016-06-06       Impact factor: 5.614

Review 3.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

Review 4.  High-density lipoprotein: a novel target for antirestenosis therapy.

Authors:  Kai Yin; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-07-15       Impact factor: 4.689

Review 5.  Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.

Authors:  Jianglin Fan; Shuji Kitajima; Teruo Watanabe; Jie Xu; Jifeng Zhang; Enqi Liu; Y Eugene Chen
Journal:  Pharmacol Ther       Date:  2014-09-30       Impact factor: 12.310

Review 6.  Atherosclerosis.

Authors:  Hong Lu; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03       Impact factor: 8.311

7.  Determinants of high-density lipoprotein (HDL) functions beyond proteome in Asian Indians: exploring the fatty acid profile of HDL phospholipids.

Authors:  Himani Thakkar; Vinnyfred Vincent; Ambuj Roy; Ajay Kumar Gautam; Rintu Kutum; Lakshmy Ramakrishnan; Sandeep Singh; Archna Singh
Journal:  Mol Cell Biochem       Date:  2021-11-29       Impact factor: 3.396

8.  HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.

Authors:  Günther Silbernagel; Bernd Genser; Christiane Drechsler; Hubert Scharnagl; Tanja B Grammer; Tatjana Stojakovic; Vera Krane; Eberhard Ritz; Christoph Wanner; Winfried März
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

9.  Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer.

Authors:  Sara Fernández-Castillejo; Laura Rubió; Álvaro Hernáez; Úrsula Catalán; Anna Pedret; Rosa-M Valls; Juana I Mosele; Maria-Isabel Covas; Alan T Remaley; Olga Castañer; Maria-José Motilva; Rosa Solá
Journal:  Mol Nutr Food Res       Date:  2017-10-26       Impact factor: 5.914

10.  MicroRNA-144 Silencing Protects Against Atherosclerosis in Male, but Not Female Mice.

Authors:  Joan Cheng; Angela Cheng; Bethan L Clifford; Xiaohui Wu; Ulf Hedin; Lars Maegdefessel; Nathalie Pamir; Tamer Sallam; Elizabeth J Tarling; Thomas Q de Aguiar Vallim
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-19       Impact factor: 10.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.